Wilfried M. Guiblet

Feb 15, 2023 | biorxiv.org | Robert W. Robey |Christina M. Fitzsimmons |Wilfried M. Guiblet |William Frye

New Results doi: https://doi.org/10.1101/2022.10.07.511310 AbstractHistone deacetylase inhibitors (HDACis) are part of a growing class of epigenetic therapies used for the treatment of cancer. While elevated levels of the efflux pump P-gp are associated with in vitro resistance to romidepsin, this mechanism does not translate to the clinic.